Humacyte regains ex-U.S. rights to Symvess from Fresenius Medical Care
Humacyte, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $1.30
+29% in 7d after detection
Post-detection moves
1h
—
1d
+15%
3d
+17%
7d
+29%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS